To overcome some of the shortcomings of classical whole virus avian influenza (AI) inactivated 17 vaccines, recombinant vector vaccines, such as recombinant Newcastle disease virus (NDV) 18 vaccines expressing the immunogenic H5 hemagglutinin of AI (rNDV-H5), have been 19 developed. The impact of H5 insertion and surface expression on NDV structure and 20 functionality of a specific bivalent rNDV-H5 vaccine was investigated here. 21
surface expression of the rNDV-H5 glycoproteins resulting in a decreased and increased number 23 of fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins, respectively, compared with 24 the NDV LaSota parental strain. Accordingly, increased hemagglutinating and neuraminidase 25 activities were observed for the rNDV-H5 vaccine. 26 Functional analysis by monoclonal antibody (mAb) neutralization demonstrated H5 involvement 27 in the rNDV-H5 entry pathway by a reduced in vitro infectivity in the presence of neutralizing 28 H5-specific mAb and confirmed the major role of the F glycoprotein in the rNDV-H5 entry 29 pathway as F-specific mAb neutralization resulted in a more important decrease of rNDV-H5 30 infectivity. However, a significantly lower impact of F-neutralization on rNDV-H5 infectivity 31 3 effect while their inherent characteristics are scarcely evaluated. The significance of this paper is 39 to evaluate the impact of the H5 insertion on the NDV structure and functionality in comparison 40 to the parental NDV vaccine, using the rNDV-H5 from Lohmann as material. This advanced 41 characterization helps to better understand the underlying mechanisms of vaccine entry and 42 could help improving vaccination. 43
INTRODUCTION 44
Newcastle disease (ND) and highly pathogenic avian influenza (HPAI) are two highly 45 contagious and economically devastating notifiable diseases of major concern to the poultry 46 industry (1). Despite intensive vaccination campaigns in most parts of the world, ND continues 47 to circulate and cause outbreaks (2). Since early 2000, the epizootic Asian clade 1 HPAI H5N1 48 virus gradually spread from Asia to Europe via wild bird movement and bird trade (3). 49
Meanwhile, HPAI H5 descendants continued to evolve, causing epizootics around the world and 50 becoming endemic in some Asian and African countries, resulting in a continuous threat to the 51 poultry sector (4). Although, whole virus inactivated AI-vaccines have demonstrated efficacy in 52 the past, the use of live replicating vaccines induce a broader range of immune responses 53 including humoral, cell-mediated, and mucosal immunity to protect against homologous and 54 heterologous clades of HPAI H5 (5). 55
The continued presence and threat imposed by both these avian viruses, emphasize the need for 56 further reinforcement of existing biosafety measures, enhanced surveillance, and improvement of 57 vaccination programs (6, 7). In this context, bivalent vaccines are valuable candidates to improve 58 simultaneously AI and ND protection in poultry (8, 9) . A recombinant ND vaccine that carries a 59 organization and the vector life cycle needed further investigations. Para-and Orthomyxoviruses, 67
represented here by NDV and AI virus (AIV) respectively, enter cells by binding to sialic acid 68 receptors using the HN and the hemagglutinin glycoproteins, respectively. To infect cells, NDV 69 uses a pH-independent entry pathway involving the F glycoprotein for fusion with the cell 70 membrane, while binding to the receptor and release of newly formed budding virions rely on the 71 HN glycoprotein (16, 17) . For AIV, the hemagglutinin glycoprotein is essential for the binding to 72 the receptor and the fusion with the endosomal membrane, whereas the release of budding virus 73 particles is mediated through the neuraminidase (NA) glycoprotein (18). AIV enters the cells 74 through a pH-dependent pathway where the acidic pH induces conformational changes in the 75 hemagglutinin glycoprotein exposing the fusion peptide to the endosomal membrane, inducing 76 the release of the genome into the cell's cytoplasm (19) . Previous vaccination trials using this 77 specific experimental rNDV-H5 vaccine in the presence of anti-NDV maternal derived 78 antibodies, demonstrated protection against heterologous HPAI H5N1 challenge (15), which 79 resulted in the hypothesis that the rNDV-H5 can enter cells by the involvement of the foreign H5 80 surface glycoprotein, as already demonstrated for a recombinant NDV-Ebola vaccine (20) . 81
The objective of the present study is to evaluate the structural and biological activities of the 82 rNDV-H5 by i) investigating H5, F and HN glycoprotein expression at the surface and ii) 83 6 The expression of the H5 protein was confirmed by WesternBlot and revealed a molecular 88 weight of 80 kDa and 75 kDa for rNDV-H5 and HP H5N1, respectively ( Figure 1 ). 89
To determine whether the H5 insertion on the rNDV-H5 surface impacted the surface 90 glycoprotein organization, the glycoprotein expression of the vaccine strain was analyzed by 91 immunogold electron microscopy (Figure 2a ) in comparison to the NDV LaSota parental strain. 92
Labeling of H5 demonstrated a significant higher number of gold particles at the rNDV-H5 93 surface (4.6±0.7 gold/virion) compared to the NDV LaSota surface background values (0.8±0.2 94 gold/virion) ( Figure 2b ). Further, significantly lower F glycoprotein expression was detected at 95 the surface of rNDV-H5 (4.3±0.3 gold/virion) compared to NDV LaSota (8.4±0.5 gold/virion). 96
In contrast, a significantly higher HN expression was revealed at the rNDV-H5 surface (25.8±1.4 97 gold/virion) compared to the NDV LaSota reference (18.4±1.9 gold/virion) ( Figure 2b ). 98
Evaluation of the rNDV-H5 HA and NA activities 99
The HA activity of serially diluted vaccine isolates demonstrated an activity of 10 4.79 TCID50/ml 100 and 10 5.52 TCID50/ml for rNDV-H5 and NDV LaSota, respectively. 101
The comparison of the NA activity of the rNDV-H5, 42582.2 RFU, and the NDV LaSota, 7424.1 102 RFU, at a concentration of 10 5.59 TCID50/ml represents a 5.7 times difference in activity ( Figure  103 3). 104
Investigation of the impact of the H5 insert on the rNDV-H5 entry pathway 105

VN test 106
The anti-F, anti-HN, and anti-H5 mAbs VN titers are displayed in Figure 4 . The anti-F mAb VN 107 titer for NDV LaSota and rNDV-H5 were comparable, 0.99±0.09 µg/ml versus 0.86±0.10 µg/ml, 108 respectively. The VN titer of the anti-HN mAb for rNDV-H5 infection (1.56±0.21 µg/ml) was 7 two times higher than for the NDV LaSota infection (0.70±0.08 µg/ml). Although it possesses a 110 VN titer for the clade 1 HPAI H5N1 virus of 1.56±0.21 µg/ml confirming the neutralizing 111 capacity of the mAb used (data not shown), the anti-H5 mAb demonstrated no neutralizing 112 capacity against the rNDV-H5. The H5-neutralization was complete for clade 1 HPAI H5N1 113 infection (data not shown), while no aspecific neutralization of the NDV LaSota infectivity was 114 confirmed (Figure 5a ). The surface expression of the hybrid H5 was confirmed by immunogold electron microscopy for 140 the rNDV-H5 vaccine under investigation as already shown (15) and in accordance with 141 previous studies for similar rNDV-H5 vaccines (11, 12, 27) . This accurate and highly sensitive 142 method revealed a reduced number of F and increased number of HN incorporation at the virion 143 surface compared with the parental LaSota strain (Figure 6a ). Due to the introduction of the H5 144 gene between phosphoprotein (P) and matrix (M) genes, a lower expression of F and HN 145 proteins, can be expected as they are downstream from the 3'end reducing their transcription 146 level (28, 29). However, here a differential impact of H5 incorporation on F and HN 147 glycoproteins surface expression was observed, indicating that the reduction of the expression of 148 F at the surface can be rather explained by competition between the CT domains of hybrid H5 149 and the F glycoproteins for their incorporation into the virion, as suggested earlier (11) . It was 150 previously demonstrated that the NDV F interacts with HN and nucleoprotein (NP) without 151 direct M interaction for surface incorporation (30). The stalk region of HN was mapped to be the 152 site of interaction with the second heptad repeat domain (HRB) (31), a membrane-proximal 153 domain of F (32), which is not present in the hybrid H5. Therefore, the H5 hybrid incorporation 9 is more likely based on an interaction with NP. The surface incorporation of HN involves 155 interaction with the F HRB domain (31) and M (30), moreover interaction with NP is suggested 156 (30). Further research is needed to evaluate the interaction between HN and other viral proteins 157 in terms of HN surface incorporation. To ensure infectivity, the balance between neuraminidase 158 and binding activities has to be maintained (33). In this study, increases of both the HA and NA 159 activities of the rNDV-H5 were measured by classical activity tests. These higher activities can 160 primarily be linked to the observed increased HN surface incorporation while the H5 surface 161 expression can only be responsible for the increased HA activity. The influence of the detected 162 HN S521R mutation, currently undescribed, on the neuraminidase activity is probably limited 163 being far away from the receptor binding and neuraminidase activity site (34). On the contrary, 164 this mutation could be involved in the increase of HA activity as it is located near the R516 165 amino acid, involved in the formation of the second sialic acid binding site (site II) (35) . 
MATERIALS AND METHODS 199
Vaccine and viruses 200
The rNDV-H5 vaccine, expressing a modified H5 ectodomain from a human HPAI H5N1 clade 201 1 strain (A/Vietnam/1203/04), and the parental NDV LaSota were provided by Lohmann Animal 202
Health GmbH (Germany) (14). The H5 insert of the rNDV-H5 had been modified into a low-203 pathogenic version to ensure vaccine safety (12). In addition, to assure surface expression, and 204 therefore the immunogenic response, the H5 transmembrane (TM) domain and cytoplasmic tail 205 (CT) were replaced by those of the NDV F glycoprotein (10, 11). The H5 gene was inserted 206 between the P and M genes of the NDV genome identified as the optimal insertion site for gene 207 expression (38). 208
As clade 1 representative, the HPAI H5N1 A/Crested-eagle/Belgium/01/2004 strain, isolated 209 from two illegally imported crested hawk eagles in 2004 in Belgium (39) , was used as H5 210 control for Western blot, neutralization, and flow cytometry assays. 211 All vaccines and virus were amplified by inoculation into the allantoic cavity of 9-11 day old 212 embryonated specific pathogen free (SPF) eggs. Five days after inoculation or at embryonic 213 death, allantoic fluids were harvested and the isolates were titrated on primary chicken embryo 214 fibroblasts (CEFs) (40) to determine the tissue culture infectious dose (TCID50/ml) (41) . 215
For Western blot and immunogold electron microscopy analysis, viral strains were purified by 216 differential centrifugation on a sucrose gradient, as previously described (42). The total protein 217 concentration of purified viruses was determined with the bicinchoninic acid assay Kit 218 (ThermoFisher Scientific, Massachusetts, USA) and was expressed in µg/ml.
12
The applied mAb's directed against NDV and AIV glycoproteins were in house produced: 221 mouse anti-NDV F 1C3 at 1.14 mg/ml (IgG1) (43); mouse anti-NDV HN 4D6 at 1.26 mg/ml 222 (IgG2a) (43); and mouse anti-AIV H55A1 at 1.05 mg/ml (IgG1) (44) . 223
Western blot 224
H5-expression was analyzed by Western blot as previously described (45 
Virus neutralization (VN) test and flow cytometry-based neutralization assay 256
A culture of primary CEFs was seeded at a concentration of 5 10 5 CEFs/ml in Leibovitz's 257 L15/McCoy's 5A (1:1) medium (Gibco, ThermoFisher Scientific, USA) supplemented with 2 % 258 fetal calf serum in 96-well plates for VN test or in T75 culture flask for flow cytometry (16, 48) 259 assay. Cells were incubated (37 °C, 5 % CO 2 ) for 24h to reach 80 % of confluence. 260
VN test 261
Two-fold serial dilutions of an initial 5 µg/ml concentration of the mAbs were incubated for 3h 262 at 37 °C with NDV LaSota or rNDV-H5 in medium supplemented with L-1-tosylamido-2-263 phenylethylchloromethyl ketone (TPCK)trypsin (Sigma Aldrich) at a final concentration of 50 264 ng/ml. Subsequently, CEFs monolayers were infected with 100 µl of the vaccine-mAbs complexes at a multiplicity of infection (MOI) of 0.01. After 24 h of incubation at 37 °C, 5 % 266 CO 2 , 100 µl of fresh medium supplemented with TPCK-trypsin was added to boost viral 267 replication. CEFs were monitored daily over a 7 day period for the presence of a cytopathic 268 effect (CPE). The VN titer of each mAb was expressed as the last mAb concentration where no 269 CPE was observed. 270
Flow cytometry assay 271
The rNDV-H5, NDV LaSota or H5N1 strains were pre-incubated for 90 min at 37 °C with 272 specific anti-H5 or anti-F mAb, concentration diluted in medium based on the VN results for 273 each mAb. Subsequently, the CEFs monolayers were infected with 4 ml of the virus-mAbs 274 complexes at a MOI of 0.01 and incubated at 37 °C. The infectious medium was replaced after 275 1h by 4 ml of complete medium supplemented with TPCK-trypsin and mAbs. After 3h at 37 °C, 276 the medium was replaced with 10 ml of fresh medium supplemented with TPCK-trypsin, and 277 incubated for 24h at 37 °C. CEFs were detached by Trypsin-EDTA 0,25 % 278 (ThermoFisherScientific) and 10 6 infected cells for each condition were labeled for 30 min at 4 279 °C with either anti-F or anti-H5 primary mAb diluted 1:50. Thereafter, infected cells were 280 labeled for 30 min at 4 °C with secondary anti-mouse IgG1 antibody coupled with fluorescein 281 isothiocyanate (FITC) diluted 1:50 (Southern Biotech, AL, USA). After overnight fixation in BD 282 cytofix (BD-Biosciences, New Jersey,USA) at 4 °C, 10 4 cells were analyzed for each condition 283 using a FACS calibur flow cytometer (BD-Biosciences). To determine the "living cells area", 284 unlabeled cells were analyzed by Side SCatter (SSC), giving a representation of the granularity, 285
and Forward SCatter (FSC), representing the size, comparison ( Figure 4A) . The "positive cells 286 area" is determined based on the fluorescence signal of cells labeled with isotype matched 287 control antibodies. The exact same "living cells area" and "positive cells area" were used for all 288 analysis. The results were expressed as the percentage of living cells post infection. 289
Sequencing of rNDV-H5 H5 and HN genes 290
Viral RNA from rNDV-H5 allantoic fluid was extracted using the High Pure Viral Nucleic Acid 291 kit (Roche, Basel, Switzerland) according to the manufacturer's recommendations. The high 292 fidelity One-step RT-PCR kit (Qiagen, Hilden, Germany) was used to obtain cDNA (49) with 293 specifically designed primers to amplify the HN and H5 genes from the extracted RNA (Table  294 1). The amplified PCR fragments were purified by agarose gel electrophoresis and sequenced 295 using the BigDye Terminator V.3.1 cycle sequencing kit (ThermoFisher Scientific) with specific 296 primers ( Table 1) 
